Slingshot Insights

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

MRK

100%

SMMT

100%

Additional Information

Additional Relevant Details Update on 9.8.16: Separately, an exploratory Phase 2 clinical trial evaluating ridinilazole against the antibiotic fidaxomicin is ongoing in Europe and the US. The results from this open-label trial are expected to help inform the design of future Phase 3 clinical trials and the commercial positioning of ridinilazole. Top-line results from this trial are expected in the second half of 2016.

https://globenewswir...

Management Comment his is an open label trial to evaluate the gut microbiomes of patients during and off the treatment. The data from this trial are expected to help inform the design of future Phase 3 trials and the commercial positioning of the drug. We would not expect a delay in any partnering activities where we await the results of this trial which we now expect in the second half of the year.

http://seekingalpha....

Additional Relevant Details Update on Oct 12 2017: This study has been completed.

https://clinicaltria...

Additional Relevant Details Update on December 15 2016: Initially expected second half 2016, top line data release has been now delayed to Q2 2017.

http://seekingalpha....

Additional Relevant Details Update on Jun 5 2017: Preclinical data released.

http://g923gvc6go14z...

Catalyst

Do you think this event is important to the companies below? How will it affect their stock price?

Additional Information

Slingshot Insights Explained